Skip to main content
Fig. 4 | Cardiovascular Diabetology

Fig. 4

From: Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk

Fig. 4

Proportion of patients included in the CARMELINA® trial with established CV disease, prevalent kidney disease, or both. *110 patients without established CV disease had eGFR ≥ 60 mL/min/1.73 m2 and UACR ≤ 300 mg/g. †Defined as albuminuria (UACR ≥ 30 mg/g or ≥ 30 μg albumin/min or ≥ 30 mg albumin/24 h) and prevalent macrovascular disease (≥ 1 of the following: confirmed history of myocardial infarction; advanced coronary artery disease; high-risk single-vessel coronary artery disease; history of ischemic or hemorrhagic stroke; presence of carotid artery disease; presence of peripheral artery disease). ‡Defined as eGFR < 60 mL/min/1.73 m2 or macroalbuminuria (UACR > 300 mg/g). CKD chronic kidney disease, CV cardiovascular, eGFR estimated glomerular filtration rate, UACR urinary albumin-to-creatinine ratio

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840